Climb Bio, Inc. CLYM Sales Milestones — Milestone Payments
Similar metrics at other companies
Other financials
Where this comes from
Reported directly by Climb Bio, Inc. in its filing.
Tagged under the XBRL concept clym:MilestonePayments.
The source filing: Climb Bio, Inc.’s 10-Q, filed May 7, 2026.
- Filed
- May 7, 2026, 7:30 AM EDT
- Fiscal quarter
- Q1 FY2026
- Calendar quarter
- Q1 2026
- Accession
- 0001193125-26-210357
The Company is obligated to (i) make payments of up to €10.0 million ($11.5 million as of March 31, 2026) upon the achievement of certain development, manufacturing and commercial milestones, including the start of a Phase 2 clinical trial for budoprutug, and (ii) make milestone payments of up to €7.0 million ($8.0 million as of March 31, 2026) upon the achievement of certain sales milestones. If the Company elects to contract ProBioGen to perform certain manufacturing services for budoprutug, the milestone payments would be reduced by €1.1 million ($1.2 million as of March 31, 2026).
Item 1. Condensed Consolidated Financial Statements (unaudited)
FAQ
- What is Climb Bio, Inc.'s sales milestones — milestone payments?
- Climb Bio, Inc. (CLYM) reported sales milestones — milestone payments of $8M in Q1 2026.
- What does sales milestones — milestone payments mean?
- This metric represents the revenue recognized from contingent payments triggered by the achievement of specific commercial sales thresholds for licensed therapeutic products. It reflects the successful market penetration and commercial performance of the company's drug candidates as they reach pre-defined sales targets under partnership or licensing agreements. These payments serve as a key indicator of the commercial viability and market adoption of the company's clinical-stage pipeline assets.
Ask your AI about Climb Bio, Inc.'s sales milestones — milestone payments.
Connect your AI assistant and compare it to peers, right in your chat.
